254 related articles for article (PubMed ID: 20042644)
1. Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.
Peng S; Adelman RA; Rizzolo LJ
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3216-25. PubMed ID: 20042644
[TBL] [Abstract][Full Text] [Related]
2. Claudin-19 and the barrier properties of the human retinal pigment epithelium.
Peng S; Rao VS; Adelman RA; Rizzolo LJ
Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1392-403. PubMed ID: 21071746
[TBL] [Abstract][Full Text] [Related]
3. VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione.
Miura Y; Klettner A; Roider J
Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4848-55. PubMed ID: 20435596
[TBL] [Abstract][Full Text] [Related]
4. Claudin-3 and claudin-19 partially restore native phenotype to ARPE-19 cells via effects on tight junctions and gene expression.
Peng S; Wang SB; Singh D; Zhao PY; Davis K; Chen B; Adelman RA; Rizzolo LJ
Exp Eye Res; 2016 Oct; 151():179-89. PubMed ID: 27593915
[TBL] [Abstract][Full Text] [Related]
5. Claudins regulate gene and protein expression of the retinal pigment epithelium independent of their association with tight junctions.
Liu F; Xu T; Peng S; Adelman RA; Rizzolo LJ
Exp Eye Res; 2020 Sep; 198():108157. PubMed ID: 32712183
[TBL] [Abstract][Full Text] [Related]
6. Effects of proinflammatory cytokines on the claudin-19 rich tight junctions of human retinal pigment epithelium.
Peng S; Gan G; Rao VS; Adelman RA; Rizzolo LJ
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):5016-28. PubMed ID: 22761260
[TBL] [Abstract][Full Text] [Related]
7. VEGF but not PlGF disturbs the barrier of retinal endothelial cells.
Deissler HL; Deissler H; Lang GK; Lang GE
Exp Eye Res; 2013 Oct; 115():162-71. PubMed ID: 23891860
[TBL] [Abstract][Full Text] [Related]
8. Characterization of barrier properties and inducible VEGF expression of several types of retinal pigment epithelium in medium-term culture.
Geisen P; McColm JR; King BM; Hartnett ME
Curr Eye Res; 2006 Sep; 31(9):739-48. PubMed ID: 16966147
[TBL] [Abstract][Full Text] [Related]
9. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.
Klettner AK; Kruse ML; Meyer T; Wesch D; Kabelitz D; Roider J
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1601-8. PubMed ID: 19597740
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
Deissler HL; Deissler H; Lang GE
Br J Ophthalmol; 2011 Aug; 95(8):1151-6. PubMed ID: 21273213
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
[TBL] [Abstract][Full Text] [Related]
12. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
Deissler HL; Deissler H; Lang GE
Br J Ophthalmol; 2012 Jul; 96(7):1023-8. PubMed ID: 22539748
[TBL] [Abstract][Full Text] [Related]
13. Effects of high glucose concentration on the barrier function and the expression of tight junction proteins in human retinal pigment epithelial cells.
Villarroel M; García-Ramírez M; Corraliza L; Hernández C; Simó R
Exp Eye Res; 2009 Dec; 89(6):913-20. PubMed ID: 19660451
[TBL] [Abstract][Full Text] [Related]
14. TNF-α disrupts morphologic and functional barrier properties of polarized retinal pigment epithelium.
Shirasawa M; Sonoda S; Terasaki H; Arimura N; Otsuka H; Yamashita T; Uchino E; Hisatomi T; Ishibashi T; Sakamoto T
Exp Eye Res; 2013 May; 110():59-69. PubMed ID: 23454586
[TBL] [Abstract][Full Text] [Related]
15. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
Terasaki H; Sakamoto T; Shirasawa M; Yoshihara N; Otsuka H; Sonoda S; Hisatomi T; Ishibashi T
Retina; 2015 May; 35(5):1007-15. PubMed ID: 25627091
[TBL] [Abstract][Full Text] [Related]
16. Different Effects of Thrombin on VEGF Secretion, Proliferation, and Permeability in Polarized and Non-polarized Retinal Pigment Epithelial Cells.
Terasaki H; Shirasawa M; Otsuka H; Yamashita T; Uchino E; Hisatomi T; Sonoda S; Sakamoto T
Curr Eye Res; 2015 Sep; 40(9):936-45. PubMed ID: 25310246
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of apical and basolateral VEGF-A and VEGF-C secretion by oxidative stress in polarized retinal pigment epithelial cells.
Kannan R; Zhang N; Sreekumar PG; Spee CK; Rodriguez A; Barron E; Hinton DR
Mol Vis; 2006 Dec; 12():1649-59. PubMed ID: 17200665
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
Klettner A; Recber M; Roider J
Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
[TBL] [Abstract][Full Text] [Related]
19. Engineering a blood-retinal barrier with human embryonic stem cell-derived retinal pigment epithelium: transcriptome and functional analysis.
Peng S; Gan G; Qiu C; Zhong M; An H; Adelman RA; Rizzolo LJ
Stem Cells Transl Med; 2013 Jul; 2(7):534-44. PubMed ID: 23734062
[TBL] [Abstract][Full Text] [Related]
20. Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells.
Deissler HL; Rehak M; Busch C; Wolf A
Exp Eye Res; 2022 Mar; 216():108945. PubMed ID: 35038456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
